<DOC>
	<DOCNO>NCT00796731</DOCNO>
	<brief_summary>The primary objective determine maximum tolerate dose ( MTD ) SAR3419 accord dose limiting toxicity ( DLTs ) observe administer single agent weekly . Secondary objective : - characterize global safety profile - evaluate pharmacokinetic ( PK ) profile SAR3419 propose dose schedule - ass preliminary evidence anti-lymphoma activity .</brief_summary>
	<brief_title>SAR3419 Administered Weekly Patients With Relapsed/Refractory CD19-positive B-cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<criteria>Diagnosis Bcell non Hodgkin 's lymphoma Relapsed refractory standard treatment curative option conventional therapy ( Patients undergone stem cell transplantation may include ) CD19 positive disease flow cytometry immunohistochemistry Burkitt 's lymphoma , Lymphoblastic lymphoma , Chronic lymphocytic leukemia ( Small lymphocytic lymphoma may include ) Evidence cerebral meningeal involvement lymphoma Patients without bidimensionally measurable disease ECOG performance status &gt; 2 Life expectancy le 3 month Chemotherapy radiation therapy investigational agent within 4 week prior enter study Previous radioimmunotherapy within 12 week Known anaphylaxis infused protein HIV , HBV HCV positivity Poor kidney , liver bone marrow function Any serious active disease comorbid condition , , opinion principle investigator , interfere safety compliance study Pregnant breastfeed woman Patients reproductive potential without effective birth control methods The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>B-cell lymphoma</keyword>
	<keyword>NHL</keyword>
</DOC>